CCO Oncology Podcast

ROS1-Alterations and Molecular Testing in Advanced NSCLC

Episode Summary

Audio podcast with clinical highlights from a live webinar covering current recommended molecular testing for ROS1-alterations in patients with non-small-cell lung cancer. Listen to the experts review and discuss their perspectives and summarize current best practices.

Episode Notes

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:

• ROS1-gene fusions in advanced lung cancer
• ROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHC
• Comparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitors
• Advantages of RNA- vs DNA-based next-generation sequencing
   

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:

To download the slides associated with this podcast discussion, please visit the program page